A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA

Trial Profile

A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2013

At a glance

  • Drugs RG 4733 (Primary) ; Dexamethasone
  • Indications CNS cancer; Haematological malignancies; Leukaemia; Lymphoma; Solid tumours; T-cell leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2013 New source identified and integrated (M.D. Anderson Cancer Center: COGADVL0919)
    • 28 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov (NCT01088763).
    • 20 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT01088763).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top